Meet Our Founder and CEO

Dr. Kumar has been the President and CEO since 2014. He founded ARKAY with a mission to provide long-term glycemic control to Type 2 diabetes patients. Dr. Kumar has a unique combination of expertise in metabolic, cardiovascular and chronic inflammatory diseases. He developed the scientific rationale, the product concept and the clinical development strategies for RK-01. Since Type 2 diabetes runs in his family, he knows first-hand the challenges of diabetes patients, limitations of the currently marketed drugs and more importantly the devastating consequences of diabetes-related complications. Under Dr. Kumar's leadership, ARKAY has reached some very important milestones.

Dr. Kumar is the inventor of the U.S. patent US 9,839,644 B2 titled "Formulations and Methods for Treating Metabolic Syndrome" and innovator of the Fixed-Dose Combination (FDC) drug technology platform **"ParamAushadam®"** derived from Sanskrit, it means "Perfect Medicine" in English**.**

Dr. Kumar has distinguished experience in academia as well in the pharmaceutical industry. As a recipient of research grants from the American Heart Association, he cloned and characterized the Angiotensin-converting enzyme gene, the rate-limiting enzyme of the Renin-Angiotensin System (RAS) and high blood pressure at the Cleveland Clinic Foundation.

During the course of his career, Dr. Kumar has held roles of increasing responsibility in small-to-medium-to-large pharmaceutical companies including Pfizer and Purdue Pharma. He has relentlessly pursued excellence in proposing new ideas and developing new hypotheses to discover and develop innovative drugs for metabolic diseases and chronic inflammatory diseases. Dr. Kumar has served as either a project leader or co-project leader of several drug discovery projects in Type 2 Diabetes, Atherosclerosis, Obesity, and Chronic Inflammatory Diseases. Some of the projects include: inhibitors of insulin-dependent hepatic gluconeogenesis, GLP-1R agonists, PPAR-δ agonists, CRF-2R activators, activators of ApoA1, inhibitors of apo(a), inhibitors of Scavenger receptor, inhibitors of TNF-alpha, inhibitors of mPGES-1, safer Celebrex™ program, TLR4 blockers, inhibitors of iNOS, FXR activators etc.

He obtained M.S. and Ph.D. in Molecular and Cell Biology from New York University, an executive MBA in Bio-Pharma Innovation from Rutgers University, and a certification for GCP (Good Clinical Practice) from ACRP (Association of Clinical Research Professionals). Prior to his 25-year career in the pharmaceutical industry, Dr. Kumar was a Research Fellow at The Cleveland Clinic Foundation, Cleveland, OH.